Ranbaxy Mum On Lipitor Plans, Advises Patience Until Nov. 30, When “Reality” Will Emerge
This article was originally published in The Pink Sheet Daily
Executive Summary
On a quarterly earnings call, Ranbaxy management seemed upbeat about their ability to come to terms with US regulators in a timely manner, but they hedged on specifics.